Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 582060, 16 pages
http://dx.doi.org/10.1155/2015/582060
Review Article

Diabetic Retinopathy: Vascular and Inflammatory Disease

1Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
2Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy
3Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
4Department of Neuroscience, Reproductive Sciences and Dentistry, University of Naples, Italy
5ICRRS Neuromed, Pozzilli, Isernia, Italy

Received 11 December 2014; Revised 3 May 2015; Accepted 13 May 2015

Academic Editor: Harald Sourij

Copyright © 2015 F. Semeraro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Diabetes Atlas, 5th edition, 2014, http://www.idf.org/diabetesatlas.
  2. M. Barot, M. R. Gokulgandhi, S. Patel, and A. K. Mitra, “Microvascular complications and diabetic retinopathy: recent advances and future implications,” Future Medicinal Chemistry, vol. 5, no. 3, pp. 301–314, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. T. Durham and I. M. Herman, “Microvascular modifications in diabetic retinopathy,” Current Diabetes Reports, vol. 11, no. 4, pp. 253–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Beltramo and M. Porta, “Pericyte loss in diabetic retinopathy: mechanisms and consequences,” Current Medicinal Chemistry, vol. 20, no. 26, pp. 3218–3225, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. R. B. Goldberg, “Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 9, pp. 3171–3182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Dell'Omo, F. Semeraro, G. Bamonte, F. Cifariello, M. R. Romano, and C. Costagliola, “Vitreous mediators in retinal hypoxic diseases,” Mediators of Inflammation, vol. 2013, Article ID 935301, 16 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Sone, Y. Kawakami, Y. Okuda et al., “Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells,” Biochemical and Biophysical Research Communications, vol. 221, no. 1, pp. 193–198, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Costagliola, “Oxidative state of glutathione in red blood cells and plasma of diabetic patients: in vivo and in vitro study,” Clinical Physiology and Biochemistry, vol. 8, no. 4, pp. 204–210, 1990. View at Google Scholar · View at Scopus
  9. T. P. Ellis, R. H. Choudhury, K. Kaul et al., “Diabetic retinopathy and atherosclerosis: is there a link?” Current Diabetes Reviews, vol. 9, no. 2, pp. 146–160, 2013. View at Google Scholar · View at Scopus
  10. C. Costagliola, V. Romano, M. de Tollis et al., “TNF-alpha levels in tears: a novel biomarker to assess the degree of diabetic retinopathy,” Mediators of Inflammation, vol. 2013, Article ID 629529, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Semeraro, A. Cancarini, F. Morescalchi et al., “Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy,” Diabetes and Metabolism, vol. 40, pp. 445–451, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Cancarini, C. Costagliola, R. dell’Omo et al., “Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy,” Minerva Endocrinologica, vol. 39, pp. 305–311, 2014. View at Google Scholar
  13. C. Costagliola, A. Daniele, R. dell'Omo et al., “Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection,” Experimental Eye Research, vol. 110, pp. 50–54, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Tarr, K. Kaul, M. Chopra, E. M. Kohner, and R. Chibber, “Pathophysiology of diabetic retinopathy,” ISRN Ophthalmology, vol. 2013, Article ID 343560, 13 pages, 2013. View at Publisher · View at Google Scholar
  15. S. F. Abcouwer, “Angiogenic factors and cytokines in diabetic retinopathy,” Journal of Clinical & Cellular Immunology, vol. 11, pp. 1–12, 2013. View at Publisher · View at Google Scholar
  16. J. Tang and T. S. Kern, “Inflammation in diabetic retinopathy,” Progress in Retinal and Eye Research, vol. 30, no. 5, pp. 343–358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. I. Patel, G. M. Saleh, P. G. Hykin, Z. J. Gregor, and I. A. Cree, “Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy,” Eye, vol. 22, no. 2, pp. 223–228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Hernàndez, R. M. Segura, A. Fonollosa, E. Carrasco, G. Francisco, and R. Simó, “Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy,” Diabetic Medicine, vol. 22, no. 6, pp. 719–722, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Funatsu, H. Yamashita, H. Noma et al., “Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 1, pp. 3–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Murugeswari, D. Shukla, A. Rajendran, R. Kim, P. Namperumalsamy, and V. Muthukkaruppan, “Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease,” Retina, vol. 28, no. 6, pp. 817–824, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. O. Simó-Servat, C. Hernández, and R. Simó, “Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy,” Mediators of Inflammation, vol. 2012, Article ID 872978, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Dal Monte, S. Rezzola, M. Cammalleri et al., “Anti-angiogenic effectiveness of the urokinase receptor-derived peptide UPARANT in a model of oxygen induced retinopathy,” Investigative Ophthalmology & Visual Science, 2015. View at Publisher · View at Google Scholar
  23. S. Rezzola, M. D. Monte, M. Belleri et al., “Therapeutic potential of anti-angiogenic multi-target N,O-sulfated E. Coli K5 polysaccharide in diabetic retinopathy,” Diabetes, 2015. View at Publisher · View at Google Scholar
  24. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Gologorsky, A. Thanos, and D. Vavvas, “Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy,” Mediators of Inflammation, vol. 2012, Article ID 629452, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Esposito, F. Nappo, R. Marfella et al., “Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress,” Circulation, vol. 106, no. 16, pp. 2067–2072, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. S. K. Lim and S. H. Park, “High glucose stimulates the expression of erythropoietin in rat glomerular epithelial cells,” Laboratory Animal Research, vol. 27, no. 3, pp. 245–250, 2011. View at Publisher · View at Google Scholar
  28. S. Yoshida, A. Yoshida, and T. Ishibashi, “Induction of IL-8, MPC-1, and bFGF by TNF-α in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 242, no. 5, pp. 409–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. R. B. Caldwell, M. Bartoli, M. A. Behzadian et al., “Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives,” Diabetes/Metabolism Research and Reviews, vol. 19, no. 6, pp. 442–455, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. Z. A. Khan and S. Chakrabarti, “Growth factors in proliferative diabetic retinopathy,” Experimental Diabesity Research, vol. 4, no. 4, pp. 287–301, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Semeraro, A. Cancarini, E. Forbice et al., “Erythropoietin and diabetic retinopathy,” Journal of Diabetes & Metabolism, vol. 4, article 2, 2013. View at Google Scholar
  32. A. Zijlstra, M. Seandel, T. A. Kupriyanova et al., “Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells,” Blood, vol. 107, no. 1, pp. 317–327, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Newton and V. M. Dixit, “Signaling in innate immunity and inflammation,” Cold Spring Harbor Perspectives in Biology, vol. 4, no. 3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. C. L. Speyer and P. A. Ward, “Role of endothelial chemokines and their receptors during inflammation,” Journal of Investigative Surgery, vol. 24, no. 1, pp. 18–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. A. H. Sprague and R. A. Khalil, “Inflammatory cytokines in vascular dysfunction and vascular disease,” Biochemical Pharmacology, vol. 78, no. 6, pp. 539–552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. C. S. Williams, M. Mann, and R. N. DuBois, “The role of cyclooxygenases in inflammation, cancer, and development,” Oncogene, vol. 18, no. 55, pp. 7908–7916, 1999. View at Google Scholar · View at Scopus
  37. P. Romagnani, L. Lasagni, F. Annunziato, M. Serio, and S. Romagnani, “CXC chemokines: the regulatory link between inflammation and angiogenesis,” Trends in Immunology, vol. 25, no. 4, pp. 201–209, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Voronov, D. S. Shouval, Y. Krelin et al., “IL-1 is required for tumor invasiveness and angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2645–2650, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Naldini, D. Leali, A. Pucci et al., “Cutting edge: IL-1β mediates the proangiogenic activity of osteopontin-activated human monocytes,” Journal of Immunology, vol. 177, no. 7, pp. 4267–4270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Leali, P. Dell'Era, H. Stabile et al., “Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis,” The Journal of Immunology, vol. 171, no. 2, pp. 1085–1093, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. A. C. Aplin, M. Gelati, E. Fogel, E. Carnevale, and R. F. Nicosia, “Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis,” Physiological Genomics, vol. 27, no. 1, pp. 20–28, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. L. S. Angelo and R. Kurzrock, “Vascular endothelial growth factor and its relationship to inflammatory mediators,” Clinical Cancer Research, vol. 13, no. 10, pp. 2825–2830, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Zheng, S. J. Howell, D. A. Hatala, K. Huang, and T. S. Kern, “Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy,” Diabetes, vol. 56, pp. 337–345, 2007. View at Publisher · View at Google Scholar
  44. N. K. Agrawal, “Targeting inflammation in diabetes: newer therapeutic options,” World Journal of Diabetes, vol. 5, no. 5, pp. 697–710, 2014. View at Publisher · View at Google Scholar
  45. A. P. Adamis, “Is diabetic retinopathy an inflammatory disease?” British Journal of Ophthalmology, vol. 86, no. 4, pp. 363–365, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Ishida, T. Usui, K. Yamashiro et al., “VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization,” Journal of Experimental Medicine, vol. 198, no. 3, pp. 483–489, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Cheng, W. Cao, R. Wen, R. H. Steinberg, and M. M. LaVail, “Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells,” Investigative Ophthalmology and Visual Science, vol. 39, no. 3, pp. 581–591, 1998. View at Google Scholar · View at Scopus
  48. N. Bhagat, R. A. Grigorian, A. Tutela, and M. A. Zarbin, “Diabetic macular edema: pathogenesis and treatment,” Survey of Ophthalmology, vol. 54, no. 1, pp. 1–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. T. C. Moore, J. E. Moore, Y. Kaji et al., “The role of advanced glycation end products in retinal microvascular leukostasis,” Investigative Ophthalmology & Visual Science, vol. 44, no. 10, pp. 4457–4464, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. A. M. Joussen, V. Poulaki, M. L. Le et al., “A central role for inflammation in the pathogenesis of diabetic retinopathy,” FASEB Journal, vol. 18, no. 12, pp. 1450–1452, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Kaji, T. Usui, S. Ishida et al., “Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products,” Investigative Ophthalmology and Visual Science, vol. 48, no. 2, pp. 858–865, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. X. Zhang, H. Zeng, S. Bao, N. Wang, and M. C. Gillies, “Diabetic macular edema: new concepts in patho-physiology and treatment,” Cell & Bioscience, vol. 4, article 27, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Noma, T. Mimura, K. Yasuda, and M. Shimura, “Role of inflammation in diabetic macular edema,” Ophthalmologica, vol. 232, no. 3, pp. 127–135, 2014. View at Publisher · View at Google Scholar
  54. Y. Mitamura, C. Harada, and T. Harada, “Role of cytokines and trophic factors in the pathogenesis of diabetic retinopathy,” Current Diabetes Reviews, vol. 1, no. 1, pp. 73–81, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Morescalchi, S. Duse, E. Gambicorti, M. R. Romano, C. Costagliola, and F. Semeraro, “Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid,” Mediators of Inflammation, vol. 2013, Article ID 269787, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Bry, R. Kivela, V. M. Leppanev, and K. Alitao, “Vascular endothelial growth factor-B in physiology and disease,” Physiological Reviews, vol. 94, pp. 779–794, 2014. View at Publisher · View at Google Scholar
  57. H. Takahashi and M. Shibuya, “The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions,” Clinical Science, vol. 109, no. 3, pp. 227–241, 2005. View at Publisher · View at Google Scholar
  58. S. Hiratsuka, Y. Kataoka, K. Nakao et al., “Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos,” Molecular and Cellular Biology, vol. 25, no. 1, pp. 355–363, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Sakurai, K. Ohgimoto, Y. Kataoka, N. Yoshida, and M. Shibuya, “Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 4, pp. 1076–1081, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Carmeliet, L. Moons, A. Luttun et al., “Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions,” Nature Medicine, vol. 7, no. 5, pp. 575–583, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. R. O. Dull, J. Yuan, Y. S. Chang, J. Tarbell, R. K. Jain, and L. L. Munn, “Kinetics of placenta growth factor/vascular endothelial growth factor synergy in endothelial hydraulic conductivity and proliferation,” Microvascular Research, vol. 61, no. 2, pp. 203–210, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. A. P. Levy, N. S. Levy, S. Wegner, and M. A. Goldberg, “Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia,” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 13333–13340, 1995. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Stein, M. Neeman, D. Shweiki, A. Itin, and E. Keshet, “Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes,” Molecular and Cellular Biology, vol. 15, no. 10, pp. 5363–5368, 1995. View at Google Scholar · View at Scopus
  64. R. J. Melder, G. C. Koenig, B. P. Witwer, N. Safabakhsh, L. L. Munn, and R. K. Jain, “During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium,” Nature Medicine, vol. 2, no. 9, pp. 992–997, 1996. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Wang, E. Xu, M. H. Elliott, M. Zhu, and Y.-Z. Le, “Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage,” Diabetes, vol. 59, no. 9, pp. 2297–2305, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. A. C. Clermont, L. P. Aiello, F. Mori, L. M. Aiello, and S.-E. Bursell, “Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy,” American Journal of Ophthalmology, vol. 124, no. 4, pp. 433–446, 1997. View at Publisher · View at Google Scholar · View at Scopus
  67. A. P. Adamis, J. W. Miller, M.-T. Bernal et al., “Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy,” American Journal of Ophthalmology, vol. 118, no. 4, pp. 445–450, 1994. View at Publisher · View at Google Scholar · View at Scopus
  68. N. Matsunaga, Y. Chikaraishi, H. Izuta et al., “Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy,” Ophthalmology, vol. 115, no. 11, pp. 1916–1922, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. J. S. Penn, A. Madan, R. B. Caldwell, M. Bartoli, R. W. Caldwell, and M. E. Hartnett, “Vascular endothelial growth factor in eye disease,” Progress in Retinal and Eye Research, vol. 27, no. 4, pp. 331–371, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. A. L. Angiolillo, C. Sgadari, D. D. Taub et al., “Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo,” The Journal of Experimental Medicine, vol. 182, no. 1, pp. 155–162, 1995. View at Publisher · View at Google Scholar · View at Scopus
  71. L. P. Aiello, R. L. Avery, P. G. Arrigg et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” The New England Journal of Medicine, vol. 331, no. 22, pp. 1480–1487, 1994. View at Publisher · View at Google Scholar · View at Scopus
  72. K. Shinoda, S. Ishida, S. Kawashima et al., “Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus,” British Journal of Ophthalmology, vol. 83, no. 7, pp. 834–837, 1999. View at Publisher · View at Google Scholar · View at Scopus
  73. E. Duh and L. P. Aiello, “Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox,” Diabetes, vol. 48, no. 10, pp. 1899–1906, 1999. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Mitamura, A. Tashimo, Y. Nakamura et al., “Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy,” Diabetes care, vol. 25, article 2352, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. Y.-S. Chen, S. F. Hackett, C.-L. Schoenfeld, M. A. Vinores, S. A. Vinores, and P. A. Campochiaro, “Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes,” British Journal of Ophthalmology, vol. 81, no. 10, pp. 919–926, 1997. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Ziche, D. Maglione, D. Ribatti et al., “Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic,” Laboratory Investigation, vol. 76, no. 4, pp. 517–531, 1997. View at Google Scholar · View at Scopus
  77. K. S. Spirin, M. Saghizadeh, S. L. Lewin, L. Zardi, M. C. Kenney, and A. V. Ljubimov, “Basement membrane and growth factor gene expression in normal and diabetic human retinas,” Current Eye Research, vol. 18, no. 6, pp. 490–499, 1999. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Khaliq, D. Foreman, A. Ahmed et al., “Increased expression of placenta growth factor in proliferative diabetic retinopathy,” Laboratory Investigation, vol. 78, no. 1, pp. 109–116, 1998. View at Google Scholar · View at Scopus
  79. R. Chiquet-Ehrismann, E. J. Mackie, C. A. Pearson, and T. Sakakura, “Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis,” Cell, vol. 47, no. 1, pp. 131–139, 1986. View at Publisher · View at Google Scholar · View at Scopus
  80. A. E. Canfield and A. M. Schor, “Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells,” Journal of Cell Science, vol. 108, no. 2, pp. 797–809, 1995. View at Google Scholar · View at Scopus
  81. Y. Mitamura, S. Takeuchi, K. Ohtsuka, A. Matsuda, N. Hiraiwa, and M. Kusakabe, “Tenascin-C levels in the vitreous of patients with proliferative diabetic retinopathy,” Diabetes Care, vol. 25, article 1899, 2002. View at Google Scholar · View at Scopus
  82. I. Immonen, K. Tervo, I. Virtanen, L. Laatikainen, and T. Tervo, “Immunohistochemical demonstration of cellular fibronectin and tenascin in human epiretinal membranes,” Acta Ophthalmologica, vol. 69, no. 4, pp. 466–471, 1991. View at Google Scholar · View at Scopus
  83. M. Hagedorn, P. Esser, P. Wiedemann, and K. Heimann, “Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy,” German Journal of Ophthalmology, vol. 2, no. 1, pp. 28–31, 1993. View at Google Scholar · View at Scopus
  84. R. Burgos, C. Mateo, A. Cantón, C. Hernández, J. Mesa, and R. Simó, “Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study,” Diabetes Care, vol. 23, no. 1, pp. 80–83, 2000. View at Publisher · View at Google Scholar · View at Scopus
  85. V. Poulaki, A. M. Joussen, N. Mitsiades, C. S. Mitsiades, E. F. Iliaki, and A. P. Adamis, “Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy,” American Journal of Pathology, vol. 165, no. 2, pp. 457–469, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Boulton, Z. Gregor, D. McLeod et al., “Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management,” British Journal of Ophthalmology, vol. 81, no. 3, pp. 228–233, 1997. View at Publisher · View at Google Scholar · View at Scopus
  87. B. M. Glaser, P. A. D'Amore, R. G. Michels, A. Patz, and A. Fenselau, “Demonstration of vasoproliferative activity from mammalian retina,” Journal of Cell Biology, vol. 84, no. 2, pp. 298–304, 1980. View at Publisher · View at Google Scholar · View at Scopus
  88. C. G. Wong, K. A. Rich, L.-H. L. Liaw, H. T. Hsu, and M. W. Berns, “Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit,” Current Eye Research, vol. 22, no. 2, pp. 140–147, 2001. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Sivalingam, J. Kenney, G. C. Brown, W. E. Benson, and L. Donoso, “Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy,” Archives of Ophthalmology, vol. 108, no. 6, pp. 869–872, 1990. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Hueber, P. Wiedemann, P. Esser, and K. Heimann, “Basic fibroblast growth factor mRNA, bFgF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR),” International Ophthalmology, vol. 20, no. 6, pp. 345–350, 1996-1997. View at Google Scholar · View at Scopus
  91. M. Hollborn, C. Krausse, I. Iandiev et al., “Glial cell expression of hepatocyte growth factor in vitreoretinal proliferative disease,” Laboratory Investigation, vol. 84, no. 8, pp. 963–972, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. C. Harada, T. Harada, H.-M. A. Quah et al., “Potential role of glial cell line-derived neurotrophic factor receptors in Müller glial cells during light-induced retinal degeneration,” Neuroscience, vol. 122, no. 1, pp. 229–235, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. G. T. Stavri, I. C. Zachary, P. A. Baskerville, J. F. Martin, and J. D. Erusalimsky, “Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia,” Circulation, vol. 92, no. 1, pp. 11–14, 1995. View at Publisher · View at Google Scholar · View at Scopus
  94. K. Matsumoto and T. Nakamura, “Emerging multipotent aspects of hepatocyte growth factor,” Journal of Biochemistry, vol. 119, no. 4, pp. 591–600, 1996. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Canton, R. Burgos, C. Hernández et al., “Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy,” British Journal of Ophthalmology, vol. 84, no. 7, pp. 732–735, 2000. View at Publisher · View at Google Scholar · View at Scopus
  96. W. Cai, S. L. Rook, Z. Y. Jiang, N. Takahara, and L. P. Aiello, “Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth,” Investigative Ophthalmology and Visual Science, vol. 41, no. 7, pp. 1885–1893, 2000. View at Google Scholar · View at Scopus
  97. I. E. Blom, R. Goldschmeding, and A. Leask, “Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?” Matrix Biology, vol. 21, no. 6, pp. 473–482, 2002. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Kita, Y. Hata, M. Miura, S. Kawahara, S. Nakao, and T. Ishibashi, “Functional characteristics of connective tissue growth factor on vitreoretinal cells,” Diabetes, vol. 56, no. 5, pp. 1421–1428, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. D. J. Kelly, Y. Zhang, R. M. Gow, S. Itescu, and R. E. Gilbert, “Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes,” Diabetes and Vascular Disease Research, vol. 2, no. 2, pp. 76–80, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. A. J. Erslev, “Erythropoietin,” The New England Journal of Medicine, vol. 324, no. 19, pp. 1339–1344, 1991. View at Publisher · View at Google Scholar · View at Scopus
  101. D. Watanabe, K. Suzuma, S. Matsui et al., “Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy,” The New England Journal of Medicine, vol. 353, no. 8, pp. 782–792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Chen, K. M. Connor, C. M. Aderman, and L. E. H. Smith, “Erythropoietin deficiency decreases vascular stability in mice,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 526–533, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. M. García-Ramírez, C. Hernández, and R. Simó, “Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and non-diabetic subjects,” Diabetes Care, vol. 31, no. 6, pp. 1189–1194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Jaquet, K. Krause, M. Tawakol-Khodai, S. Geidel, and K.-H. Kuck, “Erythropoietin and VEGF exhibit equal angiogenic potential,” Microvascular Research, vol. 64, no. 2, pp. 326–333, 2002. View at Publisher · View at Google Scholar · View at Scopus
  105. D. Ribatti, M. Presta, A. Vacca et al., “Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo,” Blood, vol. 93, no. 8, pp. 2627–2636, 1999. View at Google Scholar · View at Scopus
  106. S. P. Becerra and J. Amaral, “Erythropoietin—an endogenous retinal survival factor,” The New England Journal of Medicine, vol. 347, no. 24, pp. 1968–1970, 2002. View at Publisher · View at Google Scholar · View at Scopus
  107. Z. Z. Chong, J.-Q. Kang, and K. Maiese, “Erythropoietin is a novel vascular protectant through activation of AKt1 and mitochondrial modulation of cysteine proteases,” Circulation, vol. 106, no. 23, pp. 2973–2979, 2002. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Digicaylioglu and S. A. Lipton, “Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades,” Nature, vol. 412, no. 6847, pp. 641–647, 2001. View at Publisher · View at Google Scholar · View at Scopus
  109. C. Hernández, A. Fonollosa, M. García-Ramírez et al., “Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema,” Diabetes Care, vol. 29, no. 9, pp. 2028–2033, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. Y. Katsura, T. Okano, K. Matsuno et al., “Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy,” Diabetes Care, vol. 28, no. 9, pp. 2252–2254, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. G. L. Semenza, “Regulation of erythropoietin production. New insights into molecular mechanism of oxygen homeostasis,” Hematology/Oncology Clinics of North America, vol. 8, no. 5, pp. 863–884, 1994. View at Google Scholar · View at Scopus
  112. A. Stahl, A. Buchwald, G. Martin et al., “Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema,” Retina, vol. 30, no. 9, pp. 1524–1529, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. J. W. Fisher, “Landmark advances in the development of erythropoietin,” Experimental Biology and Medicine, vol. 235, no. 12, pp. 1398–1411, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. N. Sekiguchi, T. Inoguchi, K. Kobayashi, N. Sonoda, and H. Nawata, “Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells,” Biochemical and Biophysical Research Communications, vol. 334, no. 1, pp. 218–222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. M. B. Grant, M. E. Boulton, and A. V. Ljubimov, “Erythropoietin: when liability becomes asset in neurovascular repair,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 467–470, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. H. Takagi, D. Watanabe, K. Suzuma et al., “Novel role of erythropoietin in proliferative diabetic retinopathy,” Diabetes Research and Clinical Practice, vol. 77, no. 3, pp. S62–S64, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. N. Kubota, Y. Terauchi, T. Yamauchi et al., “Disruption of adiponectin causes insulin resistance and neointimal formation,” Journal of Biological Chemistry, vol. 277, no. 29, pp. 25863–25866, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Frystyk, L. Tarnow, T. Krarup Hansen, H.-H. Parving, and A. Flyvbjerg, “Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications,” Diabetologia, vol. 48, no. 9, pp. 1911–1918, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. B. J. Goldstein and R. Scalia, “Adiponectin: a novel adipokine linking adipocytes and vascular function,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2563–2568, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. M. I. Yilmaz, A. Sonmez, C. Acikel et al., “Adiponectin may play a part in the pathogenesis of diabetic retinopathy,” European Journal of Endocrinology, vol. 151, no. 1, pp. 135–140, 2004. View at Publisher · View at Google Scholar · View at Scopus
  121. T. Cohen, D. Nahari, L. W. Cerem, G. Neufeld, and B.-Z. Levin, “Interleukin 6 induces the expression of vascular endothelial growth factor,” The Journal of Biological Chemistry, vol. 271, no. 2, pp. 736–741, 1996. View at Publisher · View at Google Scholar · View at Scopus
  122. M. Morohoshi, K. Fujisawa, I. Uchimura, and F. Numano, “Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro,” Diabetes, vol. 45, no. 3, pp. 954–959, 1996. View at Publisher · View at Google Scholar · View at Scopus
  123. F. Legendre, P. Bogdanowicz, K. Boumediene, and J. P. Pujol, “Role of interleukin 6 (IL6)/IL-6R-induced signal transducesrs and activators of transcription and mitogen-activaded protein kinase/extracellular,” The Journal of Rheumatology, vol. 32, pp. 1307–1316, 2005. View at Google Scholar
  124. C. Symeonidis, E. Papakonstantinou, S. Androudi et al., “Interleukin-6 and the matrix metalloproteinase response in the vitreous during proliferative vitreoretinopathy,” Cytokine, vol. 54, no. 2, pp. 212–217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. D. D. Taub, M. Anver, J. J. Oppenheim, D. L. Longo, and W. J. Murphy, “T lymphocyte recruitment by interleukin-8 (IL-8): IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo,” Journal of Clinical Investigation, vol. 97, no. 8, pp. 1931–1941, 1996. View at Publisher · View at Google Scholar · View at Scopus
  126. H. Ghasemi, T. Ghazanfari, R. Yaraee, S. Faghihzadeh, and Z. M. Hassan, “Roles of IL-8 in ocular inflammations: a review,” Ocular Immunology and Inflammation, vol. 19, no. 6, pp. 401–412, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. M. C. Mocan, S. Kadayifcilar, and B. Eldem, “Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy,” Canadian Journal of Ophthalmology, vol. 41, no. 6, pp. 747–752, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. G. A. Limb, B. C. Little, A. Meager et al., “Cytokines in proliferative vitreoretinopathy,” Eye, vol. 5, pp. 686–693, 1991. View at Google Scholar · View at Scopus
  129. C. Gustavsson, C.-D. Agardh, P. Hagert, and E. Agardh, “Inflammatory markers in nondiabetic and diabetic rat retinas exposed to ischemia followed by reperfusion,” Retina, vol. 28, no. 4, pp. 645–652, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. O. Arjamaa, M. Pöllönen, K. Kinnunen, T. Ryhänen, and K. Kaarniranta, “Increased IL-6 levels are not related to NF-κB or HIF-1α transcription factors activity in the vitreous of proliferative diabetic retinopathy,” Journal of Diabetes and its Complications, vol. 25, no. 6, pp. 393–397, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. I. K. Oh, S.-W. Kim, J. Oh, T. S. Lee, and K. Huh, “Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy,” Current Eye Research, vol. 35, no. 12, pp. 1116–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. G. Guarda and A. So, “Regulation of inflammasome activity,” Immunology, vol. 130, no. 3, pp. 329–336, 2010. View at Publisher · View at Google Scholar · View at Scopus
  133. S. G. Elner, V. M. Elner, G. J. Jaffe, A. Stuart, S. L. Kunkel, and R. M. Strieter, “Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy,” Current Eye Research, vol. 14, no. 11, pp. 1045–1053, 1995. View at Publisher · View at Google Scholar · View at Scopus
  134. J. T. Rosenbaum, J. R. Samples, S. H. Hefeneider, and E. L. Howes, “Ocular inflammatory effects of intravitreal interleukin 1,” Archives of Ophthalmology, vol. 105, no. 8, pp. 1117–1120, 1987. View at Publisher · View at Google Scholar · View at Scopus
  135. J. A. Vincent and S. Mohr, “Inhibition of caspase-1/interleukin-1β signaling prevents degeneration of retinal capillaries in diabetes and galactosemia,” Diabetes, vol. 56, no. 1, pp. 224–230, 2007. View at Publisher · View at Google Scholar · View at Scopus
  136. R. A. Kowluru and S. Odenbach, “Role of interleukin-1β in the pathogenesis of diabetic retinopathy,” British Journal of Ophthalmology, vol. 88, no. 10, pp. 1343–1347, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. N. Parameswaran and S. Patial, “Tumor necrosis factor-a signaling in macrophages,” Critical Reviews in Eukaryotic Gene Expression, vol. 20, no. 2, pp. 87–103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. G. Tezel and M. B. Wax, “Increased production of tumor necrosis factor-α by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells,” Journal of Neuroscience, vol. 20, no. 23, pp. 8693–8700, 2000. View at Google Scholar · View at Scopus
  139. E. A. Carswell, L. J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson, “An endotoxin induced serum factor that cuases necrosis of tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 72, no. 9, pp. 3666–3670, 1975. View at Publisher · View at Google Scholar · View at Scopus
  140. C. A. Aveleira, C.-M. Lin, S. F. Abcouwer, A. F. Ambrósio, and D. A. Antonetti, “TNF-α signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability,” Diabetes, vol. 59, no. 11, pp. 2872–2882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  141. M. G. Madigan, A. A. Sadun, N. S. Rao, P. U. Dugel, W. N. Tenhula, and P. S. Gill, “Tumor necrosis factor-alpha (TNF-α)-induced optic neuropathy in rabbits,” Neurological Research, vol. 18, no. 2, pp. 176–184, 1996. View at Google Scholar · View at Scopus
  142. S. Majka, P. G. McGuire, and A. Das, “Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization,” Investigative Ophthalmology and Visual Science, vol. 43, no. 1, pp. 260–266, 2002. View at Google Scholar · View at Scopus
  143. S. E. Kahn, R. L. Hull, and K. M. Utzschneider, “Mechanisms linking obesity to insulin resistance and type 2 diabetes,” Nature, vol. 444, no. 7121, pp. 840–846, 2006. View at Publisher · View at Google Scholar · View at Scopus
  144. S. Doganay, C. Evereklioglu, H. Er et al., “Comparison of serum NO, TNF-α, IL-1β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus,” Eye, vol. 16, no. 2, pp. 163–170, 2002. View at Publisher · View at Google Scholar · View at Scopus
  145. Y. Behl, P. Krothapalli, T. Desta, A. DiPiazza, S. Roy, and D. T. Graves, “Diabetes-enhanced tumor necrosis factor-α production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy,” The American Journal of Pathology, vol. 172, no. 5, pp. 1411–1418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  146. Y. Behl, P. Krothapalli, T. Desta, S. Roy, and D. T. Graves, “FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats,” Diabetes, vol. 58, no. 4, pp. 917–925, 2009. View at Publisher · View at Google Scholar
  147. H. Huang, J. K. Gandhi, X. Zhong et al., “TNFα is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis,” Investigative Ophthalmology and Visual Science, vol. 52, no. 3, pp. 1336–1344, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. M. T. Lotze and K. J. Tracey, “High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal,” Nature Reviews Immunology, vol. 5, no. 4, pp. 331–342, 2005. View at Publisher · View at Google Scholar · View at Scopus
  149. N. Arimura, Y. Ki-I, T. Hashiguchi et al., “Intraocular expression and release of high-mobility group box 1 protein in retinal detachment,” Laboratory Investigation, vol. 89, no. 3, pp. 278–289, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. T. Watanabe, H. Keino, Y. Sato, A. Kudo, H. Kawakami, and A. A. Okada, “High mobility group box protein-1 in experimental autoimmune uveoretinitis,” Investigative Ophthalmology & Visual Science, vol. 50, no. 5, pp. 2283–2290, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. S. Yang, K. Hirooka, Y. Liu et al., “Deleterious role of anti-high mobility group box 1 monoclonal antibody in retinal ischemia-reperfusion injury,” Current Eye Research, vol. 36, no. 11, pp. 1037–1046, 2011. View at Publisher · View at Google Scholar · View at Scopus
  152. A. M. A. El-Asrar, M. I. Nawaz, D. Kangave et al., “High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy,” Molecular Vision, vol. 17, pp. 1829–1838, 2011. View at Google Scholar · View at Scopus
  153. J.-J. Lee, C.-C. Hsiao, I.-H. Yang et al., “High-mobility group box 1 protein is implicated in advanced glycation end products-induced vascular endothelial growth factor a production in the rat retinal ganglion cell line RGC-5,” Molecular Vision, vol. 18, pp. 838–850, 2012. View at Google Scholar · View at Scopus
  154. V. Jakuš and N. Rietbrock, “Advanced glycation end-products and the progress of diabetic vascular complications,” Physiological Research, vol. 53, no. 2, pp. 131–142, 2004. View at Google Scholar · View at Scopus
  155. P. J. Barnes, “Nuclear factor-κB,” International Journal of Biochemistry and Cell Biology, vol. 29, no. 6, pp. 867–870, 1997. View at Publisher · View at Google Scholar · View at Scopus
  156. S. Kiechl, J. Wittmann, A. Giaccari et al., “Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus,” Nature Medicine, vol. 19, no. 3, pp. 358–363, 2013. View at Publisher · View at Google Scholar · View at Scopus
  157. N. Sakai, H. L. van Sweringen, R. Schuster et al., “Receptor activator of nuclear factor-κB ligand (RANKL) protects against hepatic ischemia/reperfusion injury in mice,” Hepatology, vol. 55, no. 3, pp. 888–897, 2012. View at Publisher · View at Google Scholar · View at Scopus
  158. G. L. Semenza, “Hydroxylation of HIF-1: oxygen sensing at the molecular level,” Physiology, vol. 19, no. 4, pp. 176–182, 2004. View at Publisher · View at Google Scholar · View at Scopus
  159. O. Arjamaa and M. Nikinmaa, “Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors,” Experimental Eye Research, vol. 83, no. 3, pp. 473–483, 2006. View at Publisher · View at Google Scholar · View at Scopus
  160. C. Treins, S. Giorgetti-Peraldi, J. Murdaca, M.-N. Monthouël-Kartmann, and E. van Obberghen, “Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I,” Molecular Endocrinology, vol. 19, no. 5, pp. 1304–1317, 2005. View at Publisher · View at Google Scholar · View at Scopus
  161. V. Poulaki, W. Qin, A. M. Joussen et al., “Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1α and VEGF,” The Journal of Clinical Investigation, vol. 109, no. 6, pp. 805–815, 2002. View at Publisher · View at Google Scholar · View at Scopus
  162. A. M. A. El-Asrar, L. Missotten, and K. Geboes, “Expression of hypoxia-inducible factor-1 alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes,” British Journal of Ophthalmology, vol. 91, no. 6, pp. 822–826, 2007. View at Publisher · View at Google Scholar · View at Scopus
  163. S. Frede, C. Stockmann, P. Freitag, and J. Fandrey, “Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-κB,” Biochemical Journal, vol. 396, no. 3, pp. 517–527, 2006. View at Publisher · View at Google Scholar · View at Scopus
  164. M. Gharaee-Kermani, E. M. Denholm, and S. H. Phan, “Costimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors,” The Journal of Biological Chemistry, vol. 271, no. 30, pp. 17779–17784, 1996. View at Publisher · View at Google Scholar · View at Scopus
  165. K. H. Hong, J. Ryu, and K. H. Han, “Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A,” Blood, vol. 105, no. 4, pp. 1405–1407, 2005. View at Publisher · View at Google Scholar · View at Scopus
  166. P. Esser, K. Heimann, and P. Wiedemann, “Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations,” British Journal of Ophthalmology, vol. 77, no. 11, pp. 731–733, 1993. View at Publisher · View at Google Scholar · View at Scopus
  167. Y. Mitamura, S. Takeuchi, A. Matsuda, Y. Tagawa, Y. Mizue, and J. Nishihira, “Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy,” Ophthalmologica, vol. 215, no. 6, pp. 415–418, 2001. View at Publisher · View at Google Scholar · View at Scopus
  168. A. Tashimo, Y. Mitamura, S. Nagai et al., “Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy,” Diabetic Medicine, vol. 21, no. 12, pp. 1292–1297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  169. W. Zhang, H. Liu, M. Al-Shabrawey, R. Caldwell, and R. Caldwell, “Inflammation and diabetic retinal microvascular complications,” Journal of Cardiovascular Disease Research, vol. 2, no. 2, pp. 96–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  170. A. M. Abu El-Asrar, S. Struyf, D. Kangave, K. Geboes, and J. Van Damme, “Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy,” European Cytokine Network, vol. 17, no. 3, pp. 155–165, 2006. View at Google Scholar · View at Scopus
  171. Y. Wakabayashi, Y. Usui, Y. Okunuki et al., “Increased levels of monokine induced by interferon-gamma (Mig) in the vitreous of patients with diabetic retinopathy,” Diabetic Medicine, vol. 25, pp. 875–877, 2008. View at Publisher · View at Google Scholar
  172. R. Salcedo and J. J. Oppenheim, “Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses,” Microcirculation, vol. 10, no. 3-4, pp. 359–370, 2003. View at Publisher · View at Google Scholar · View at Scopus
  173. J. M. Butler, S. M. Guthrie, M. Koc et al., “SDF-1 is both necessary and sufficient to promote proliferative retinopathy,” Journal of Clinical Investigation, vol. 115, no. 1, pp. 86–93, 2005. View at Publisher · View at Google Scholar · View at Scopus
  174. M. B. Grant, A. Afzal, P. Spoerri, H. Pan, L. C. Shaw, and R. N. Mames, “The role of growth factors in the pathogenesis of diabetic retinopathy,” Expert Opinion on Investigational Drugs, vol. 13, no. 10, pp. 1275–1293, 2004. View at Publisher · View at Google Scholar · View at Scopus
  175. J.-J. You, C.-H. Yang, J.-S. Huang, M.-S. Chen, and C.-M. Yang, “Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis,” Investigative Ophthalmology and Visual Science, vol. 48, no. 11, pp. 5290–5298, 2007. View at Publisher · View at Google Scholar · View at Scopus
  176. L. Y. Chen, Y. H. Zhuo, Y. H. Li et al., “Expression of stromal cell-derived factor-1 in diabetic retinopathy,” Chinese Medical Journal, vol. 123, no. 8, pp. 984–988, 2010. View at Publisher · View at Google Scholar · View at Scopus
  177. Y. Mitamura, S. Takeuchi, A. Matsuda, Y. Tagawa, Y. Mizue, and J. Nishihira, “Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy,” British Journal of Ophthalmology, vol. 84, no. 6, pp. 636–639, 2000. View at Publisher · View at Google Scholar · View at Scopus
  178. M. Lu, V. L. Perez, N. Ma et al., “VEGF increases retinal vascular ICAM-1 expression in vivo,” Investigative Ophthalmology and Visual Science, vol. 40, no. 8, pp. 1808–1812, 1999. View at Google Scholar · View at Scopus
  179. D. S. McLeod, D. J. Lefer, C. Merges, and G. A. Lutty, “Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid,” The American Journal of Pathology, vol. 147, no. 3, pp. 642–653, 1995. View at Google Scholar · View at Scopus
  180. F. C. Barouch, K. Miyamoto, J. R. Allport et al., “Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes,” Investigative Ophthalmology and Visual Science, vol. 41, no. 5, pp. 1153–1158, 2000. View at Google Scholar · View at Scopus
  181. C. Hernández, R. Burgos, A. Cantón, J. García-Arumí, R. M. Segura, and R. Simó, “Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study,” Diabetes Care, vol. 24, no. 3, pp. 516–521, 2001. View at Publisher · View at Google Scholar · View at Scopus
  182. J. Adamiec-Mroczek, J. Oficjalska-Młyńczak, and M. Misiuk-Hojło, “Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: analysis of vitreous samples,” Cytokine, vol. 49, no. 3, pp. 269–274, 2010. View at Publisher · View at Google Scholar · View at Scopus
  183. M. Murata, K. Noda, J. Fukuhara et al., “Soluble vascular adhesion protein-1 accumulates in proliferative diabetic retinopathy,” Investigative Ophthalmology and Visual Science, vol. 53, no. 7, pp. 4055–4062, 2012. View at Publisher · View at Google Scholar · View at Scopus
  184. C. Baudouin, D. Fredj-Reygrobellet, F. Brignole, P. Lapalus, and P. Gastaud, “MHC class II antigen expression by ocular cells in proliferative diabetic retinopathy,” Fundamental and Clinical Pharmacology, vol. 7, no. 9, pp. 523–530, 1993. View at Publisher · View at Google Scholar · View at Scopus
  185. B.-B. Gao, X. Chen, N. Timothy, L. P. Aiello, and E. P. Feener, “Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy,” Journal of Proteome Research, vol. 7, no. 6, pp. 2516–2525, 2008. View at Publisher · View at Google Scholar · View at Scopus
  186. H. Zong, M. Ward, A. Madden et al., “Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE),” Diabetologia, vol. 53, no. 12, pp. 2656–2666, 2010. View at Publisher · View at Google Scholar · View at Scopus
  187. A. M. A. El-Asrar, L. Missotten, and K. Geboes, “Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes,” The British Journal of Ophthalmology, vol. 92, no. 11, pp. 1534–1539, 2008. View at Publisher · View at Google Scholar · View at Scopus
  188. A. M. Joussen, V. Poulaki, N. Mitsiades et al., “Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression,” The FASEB Journal, vol. 16, no. 3, pp. 438–440, 2002. View at Google Scholar · View at Scopus
  189. S. P. Ayalasomayajula and U. B. Kompella, “Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model,” European Journal of Pharmacology, vol. 458, no. 3, pp. 283–289, 2003. View at Publisher · View at Google Scholar · View at Scopus
  190. M. L. Schwartzman, P. Iserovich, K. Gotlinger et al., “Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy,” Diabetes, vol. 59, no. 7, pp. 1780–1788, 2010. View at Publisher · View at Google Scholar · View at Scopus
  191. R. A. Gubitosi-Klug, R. Talahalli, Y. Du, J. L. Nadler, and T. S. Kern, “5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy,” Diabetes, vol. 57, no. 5, pp. 1387–1393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  192. G. A. Lutty, D. S. McLeod, C. Merges, A. Diggs, and J. Plouét, “Localization of vascular endothelial growth factor in human retina and choroid,” Archives of Ophthalmology, vol. 114, no. 8, pp. 971–977, 1996. View at Publisher · View at Google Scholar · View at Scopus
  193. Early Treatment Diabetic Retinopathy Study Research Group, “Effects of aspirin treatment on diabetic retionopathy. ETDRS report number 8,” Ophthalmology, vol. 98, pp. 757–777, 1991. View at Publisher · View at Google Scholar
  194. S. Nakao, M. Arima, K. Ishikawa et al., “Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis,” Investigative Ophthalmology and Visual Science, vol. 53, no. 7, pp. 4323–4328, 2012. View at Publisher · View at Google Scholar · View at Scopus